These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

563 related articles for article (PubMed ID: 32697374)

  • 1. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
    Gaspari AA; Tyring S
    Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
    Molinelli E; Campanati A; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of biologics in psoriasis.
    Kamata M; Tada Y
    J Dermatol; 2018 Mar; 45(3):279-286. PubMed ID: 29226369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
    Green LJ; Yamauchi PS; Kircik LH
    J Drugs Dermatol; 2019 Aug; 18(8):776-788. PubMed ID: 31424708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition.
    Yamauchi PS; Bagel J
    J Drugs Dermatol; 2015 Mar; 14(3):244-53. PubMed ID: 25738846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.
    Tan WS; Kelly S; Pitzalis C
    Expert Rev Clin Immunol; 2017 Mar; 13(3):207-222. PubMed ID: 27690678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.
    Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F
    Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of biologics targeting IL-17 and IL-23 in the treatment of moderate-to-severe plaque psoriasis: A systematic review and meta-analysis of randomized controlled trials.
    Cui L; Chen R; Subedi S; Yu Q; Gong Y; Chen Z; Shi Y
    Int Immunopharmacol; 2018 Sep; 62():46-58. PubMed ID: 29990694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic therapies targeting the interleukin (IL)-23/IL-17 immune axis for the treatment of moderate-to-severe plaque psoriasis: a systematic review and meta-analysis.
    Erichsen CY; Jensen P; Kofoed K
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):30-38. PubMed ID: 31419343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies in psoriasis: a systematic review.
    Lee EB; Amin M; Bhutani T; Wu JJ
    Cutis; 2018 Mar; 101(3S):5-9. PubMed ID: 29718027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents.
    Shibuya T; Honma M; Iinuma S; Iwasaki T; Takahashi H; Ishida-Yamamoto A
    J Dermatol; 2018 Jun; 45(6):710-714. PubMed ID: 29655215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological treatment for erythrodermic psoriasis.
    Dogra S; Mehta H
    Expert Opin Biol Ther; 2022 Dec; 22(12):1531-1543. PubMed ID: 36154361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review.
    Maliyar K; Crowley EL; Rodriguez-Bolanos F; O'Toole A; Gooderham MJ
    J Cutan Med Surg; 2019; 23(4):428-435. PubMed ID: 30938189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis.
    Lee MP; Wu KK; Lee EB; Wu JJ
    Cutis; 2020 Oct; 106(4):199-205. PubMed ID: 33186421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.